Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $953,691.36 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the sale, the vice president directly owned 38,970 shares of the company’s stock, valued at approximately $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $83.06 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The company has a market capitalization of $48.20 billion, a PE ratio of 35.80, a P/E/G ratio of 3.73 and a beta of 0.97. The company has a 50 day moving average price of $81.62 and a 200-day moving average price of $79.05. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period last year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Level Four Advisory Services LLC raised its holdings in Edwards Lifesciences by 3.7% during the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after buying an additional 119 shares during the period. Colonial Trust Co SC increased its position in shares of Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after acquiring an additional 120 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Edwards Lifesciences by 9.8% during the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 130 shares during the period. Prosperity Consulting Group LLC lifted its position in shares of Edwards Lifesciences by 3.2% in the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after acquiring an additional 132 shares in the last quarter. Finally, Howard Capital Management Inc. lifted its position in shares of Edwards Lifesciences by 3.3% in the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after acquiring an additional 132 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on EW shares. Jefferies Financial Group set a $98.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 29th. Stifel Nicolaus set a $100.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday, December 5th. The Goldman Sachs Group set a $104.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Friday, October 31st. Truist Financial set a $92.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, December 5th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $93.30.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.